Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Reps. Diana DeGette (D-Colo.) and Charlie Dent (R-Pa.) June 24 introduced a measure (H.R. 2376) to establish an ethical framework for oversight of embryonic and adult stem cell research funded by the National Institutes of Health.
According to a June 27 statement, the proposed Stem Cell Research Advancement Act would bring certainty to the scientific community pursuing lifesaving cures and treatments using the technology. The legislation would put into statute a framework to ensure such critical research can be conducted unimpeded by political interference, DeGette said in the statement.
H.R. 2376 would support embryonic stem cell research and codify NIH's guidelines for carrying out both embryonic and adult human stem cell research. It also would require NIH to review its guidelines at least every three years and make periodic updates as scientifically warranted.
The ethical requirements defined by the bill would mandate that stem cells be derived from human embryos donated from in vitro fertilization clinics that were created for reproductive purposes, but are in excess of clinical needs. The donated embryos would never be implanted in a woman, and otherwise would be discarded. The individuals who had sought reproductive treatment to begin with would have to donate the embryos with written informed consent and without any financial or other inducements.
The legislation also specifically would prohibit the use of federal funding for human cloning, in keeping with the NIH guidelines.
Several years have passed since the original Stem Cell Research Enhancement Act, drafted by DeGette and former Rep. Mike Castle (R-Del.), was passed and twice vetoed by then-President George W. Bush. During that time, according to the statement, the field of human stem cell research has progressed steadily.
The representatives said H.R. 2376 has been updated to keep current with the expanding field of stem cell research and responds to calls on Congress to provide lasting support to this field of research.
Full text of H.R. 2376 is available at http://thomas.loc.gov/cgi-bin/query/z?c112:H.R.2376 :.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)